| Most studies assessing the effects of beta-blockers were carried
out with traditional, beta(1)-selective beta-blockers, such as metoprolol
and atenolol. Pathophysiologic and pharmacologic studies have documented
that not all beta-blockers are created equal. In particular, the pharmacologic
and clinical profiles of the newer, vasodilating beta-blockers, such
as carvedilol, have been shown to differ from those of the traditional
beta-blockers. These differences, although relevant in the younger
patient with hypertension, are particularly important in elderly patients
in whom traditional beta-blockers may not be as effective or as well
tolerated as the newer vasodilating agents. |
